HK1221964A1 - Antigen binding proteins that bind pd-1 pd-1 - Google Patents

Antigen binding proteins that bind pd-1 pd-1

Info

Publication number
HK1221964A1
HK1221964A1 HK16110210.5A HK16110210A HK1221964A1 HK 1221964 A1 HK1221964 A1 HK 1221964A1 HK 16110210 A HK16110210 A HK 16110210A HK 1221964 A1 HK1221964 A1 HK 1221964A1
Authority
HK
Hong Kong
Prior art keywords
bind
antigen binding
binding proteins
proteins
antigen
Prior art date
Application number
HK16110210.5A
Other languages
Chinese (zh)
Inventor
Heyue Zhou
Barbara A Swanson
John Dixon Gray
Gunnar F Kaufmann
Edwige Gros
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of HK1221964A1 publication Critical patent/HK1221964A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16110210.5A 2013-05-31 2016-08-26 Antigen binding proteins that bind pd-1 pd-1 HK1221964A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361829941P 2013-05-31 2013-05-31
PCT/US2014/040420 WO2014194302A2 (en) 2013-05-31 2014-05-31 Antigen binding proteins that bind pd-1

Publications (1)

Publication Number Publication Date
HK1221964A1 true HK1221964A1 (en) 2017-06-16

Family

ID=51985349

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16110210.5A HK1221964A1 (en) 2013-05-31 2016-08-26 Antigen binding proteins that bind pd-1 pd-1
HK16114289A HK1238648A1 (en) 2013-05-31 2016-12-15 Antigen binding proteins that bind pd-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16114289A HK1238648A1 (en) 2013-05-31 2016-12-15 Antigen binding proteins that bind pd-1

Country Status (7)

Country Link
US (4) US9676853B2 (en)
EP (1) EP3004169B1 (en)
JP (4) JP6563906B2 (en)
CN (2) CN105683217B (en)
CA (2) CA3175360C (en)
HK (2) HK1221964A1 (en)
WO (1) WO2014194302A2 (en)

Families Citing this family (366)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2734205T3 (en) 2011-07-21 2018-06-14 Tolero Pharmaceuticals Inc Heterocyclic Protein Kinase Inhibitors
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
SI3702373T1 (en) * 2013-09-13 2022-11-30 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
EA035037B1 (en) 2013-12-12 2020-04-21 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
AU2015228372B2 (en) 2014-03-12 2018-05-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
TWI693232B (en) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
KR102003754B1 (en) 2014-07-03 2019-07-25 베이진 엘티디 Anti-PD-L1 Antibodies and Their Use as Therapeutics and Diagnostics
US10428146B2 (en) 2014-07-22 2019-10-01 Cb Therapeutics, Inc. Anti PD-1 antibodies
CN118388646A (en) 2014-08-05 2024-07-26 中美冠科生物技术（太仓）有限公司 Anti-PD-L1 antibodies
GB201419084D0 (en) * 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
CN114702586A (en) 2015-03-13 2022-07-05 西托姆克斯治疗公司 anti-PDL 1 antibodies, activatable anti-PDL 1 antibodies, and methods of use thereof
MA53355A (en) 2015-05-29 2022-03-16 Agenus Inc ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF
TWI773646B (en) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 Lag-3-binding molecules and methods of use thereof
TW201709929A (en) 2015-06-12 2017-03-16 宏觀基因股份有限公司 Combination therapy for the treatment of cancer
FI3313441T3 (en) 2015-06-24 2024-03-28 Janssen Biotech Inc Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
CA2991976A1 (en) * 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
SG10201906059VA (en) * 2015-07-30 2019-08-27 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
EA201890456A1 (en) 2015-08-07 2018-07-31 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ NEW FUSED POLYPEPTIDE SPECIFIC WITH RESPECT TO LAG-3 AND PD-1
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
BR112018002824A2 (en) * 2015-08-11 2018-11-06 Open Monoclonal Tech Inc antibody, polynucleotide, vector, cell, methods to express the antibody, to treat a condition associated with pd-1 and to treat a condition in a subject, kit, pharmaceutical composition and use of the antibody
PE20181322A1 (en) 2015-09-01 2018-08-14 Agenus Inc ANTI-PD1 ANTIBODY AND ITS METHODS OF USE
EP3356551B1 (en) 2015-09-29 2020-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining the metabolic status of b-lymphomas
WO2017058859A1 (en) * 2015-09-29 2017-04-06 Celgene Corporation Pd-1 binding proteins and methods of use thereof
EP3356416B1 (en) * 2015-09-29 2021-03-24 Shanghai Zhangjiang Biotechnology Co., Ltd Pd-1 antibodies and uses thereof
MA43053A (en) 2015-09-30 2018-08-08 Janssen Biotech Inc ANTAGONIST ANTIBODIES BINDING SPECIFICALLY TO HUMAN CD40 AND METHODS OF USE
JP7320944B2 (en) 2015-10-08 2023-08-04 マクロジェニクス，インコーポレーテッド Molecules that specifically bind to B7-H3 and molecules that specifically bind to PD-1
CR20180234A (en) 2015-11-03 2018-09-11 Janssen Biotech Inc Antibodies specifically binding pd-1 and their uses
EP3389714A4 (en) 2015-12-14 2019-11-13 MacroGenics, Inc. Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
US10392442B2 (en) 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
US20200264165A1 (en) 2016-01-04 2020-08-20 Inserm (Institut National De La Sante Et De Larecherche Medicale) Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
US10759859B2 (en) 2016-01-14 2020-09-01 Bps Bioscience, Inc. Anti-PD-1 antibodies and uses thereof
KR20190026642A (en) * 2016-01-29 2019-03-13 소렌토 쎄라퓨틱스, 인코포레이티드 The antigen-binding protein that binds to PD-L1
KR20180107151A (en) 2016-02-17 2018-10-01 노파르티스 아게 TGF beta 2 antibody
NZ749355A (en) 2016-05-27 2023-04-28 Agenus Inc Anti-tim-3 antibodies and methods of use thereof
EP3463457B1 (en) 2016-06-02 2023-06-28 Bristol-Myers Squibb Company Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma
FI3464368T3 (en) 2016-06-02 2023-09-12 Bristol Myers Squibb Co Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
KR20190015408A (en) * 2016-06-03 2019-02-13 브리스톨-마이어스 스큅 컴퍼니 Anti-PD-1 antibody for use in methods of treating tumors
ES2897964T3 (en) 2016-06-03 2022-03-03 Bristol Myers Squibb Co Use of anti-PD-1 antibody in the treatment of patients with colorectal cancer
EP3463454A1 (en) 2016-06-03 2019-04-10 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
WO2017214182A1 (en) * 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
EP3468581A1 (en) 2016-06-13 2019-04-17 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
WO2017220990A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
NZ749997A (en) 2016-07-05 2022-11-25 Beigene Ltd Combination of a pd-l antagonist and a raf inhibitor for treating cancer
ES2971881T3 (en) 2016-08-19 2024-06-10 Beigene Switzerland Gmbh Combination of zanubrutinib with an anti-cd20 or anti-pd-1 antibody for use in cancer treatment
CN107814845B (en) * 2016-09-14 2021-02-09 浙江特瑞思药业股份有限公司 Novel anti-PD-1 nano antibody and application thereof
JP2019534859A (en) 2016-09-19 2019-12-05 セルジーン コーポレイション Method for treating vitiligo using PD-1 binding protein
EA201990747A1 (en) 2016-09-19 2019-10-31 METHODS FOR TREATING IMMUNE DISORDERS WITH APPLICATION OF PROTEINS BINDING PD – 1
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
KR20240019398A (en) 2016-10-28 2024-02-14 브리스톨-마이어스 스큅 컴퍼니 Methods of treating urothelial carcinoma using an anti-pd-1 antibody
CN110072890B (en) 2016-11-03 2022-11-29 百时美施贵宝公司 Activatable anti-CTLA-4 antibodies and uses thereof
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
SI3551660T1 (en) 2016-12-07 2024-02-29 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
BR112019011582A2 (en) 2016-12-07 2019-10-22 Agenus Inc. antibodies and their methods of use
CN106519034B (en) * 2016-12-22 2020-09-18 鲁南制药集团股份有限公司 anti-PD-1 antibodies and uses thereof
KR20190103226A (en) 2017-01-13 2019-09-04 아게누스 인코포레이티드 T cell receptor that binds to NY-ESO-1 and methods of use thereof
WO2018134279A1 (en) 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Novel fusion polypeptides specific for lag-3 and pd-1
WO2018134784A1 (en) 2017-01-20 2018-07-26 Novartis Ag Combination therapy for the treatment of cancer
CN108341871A (en) * 2017-01-24 2018-07-31 三生国健药业（上海）股份有限公司 Anti- PD-1 monoclonal antibodies and its preparation method and application
EP3573989A4 (en) 2017-01-25 2020-11-18 Beigene, Ltd. Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
DK3579874T3 (en) 2017-02-10 2021-10-11 Novartis Ag 1- (4-AMINO-5-BROMO-6- (1H-PYRAZOL-1-YL) PYRIMIDIN-2-YL) -1H-PYRAZOL-4-OL AND ITS USE FOR CANCER TREATMENT
TWI674261B (en) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 modulators
BR112019017628A2 (en) 2017-02-24 2020-07-07 Macrogenics, Inc. cd137 x ta binding molecule, pharmaceutical compositions, use of cd137 x ta binding molecule, cd137 binding molecule, use of cd137 binding molecule, her2 / neu binding molecule, use of her2 binding molecule / neu, and use of a composition
CN110637031B (en) 2017-03-04 2024-04-16 湘潭腾华生物科技有限公司 Recombinant antibodies to programmed death protein 1 (PD-1) and uses thereof
WO2018172508A1 (en) 2017-03-24 2018-09-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
JP7458188B2 (en) 2017-03-31 2024-03-29 ブリストル－マイヤーズ スクイブ カンパニー How to treat tumors
TWI788340B (en) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 Anti-icos agonist antibodies and uses thereof
KR102629972B1 (en) 2017-04-13 2024-01-29 아게누스 인코포레이티드 Anti-CD137 antibody and methods of using the same
SG11201909516VA (en) 2017-04-14 2019-11-28 Tollnine Inc Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
AR111651A1 (en) 2017-04-28 2019-08-07 Novartis Ag CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES
US11021537B2 (en) 2017-05-01 2021-06-01 Agenus Inc. Anti-TIGIT antibodies and methods of use thereof
AR111760A1 (en) 2017-05-19 2019-08-14 Novartis Ag COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS THROUGH INTRATUMORAL ADMINISTRATION
HUE065242T2 (en) 2017-05-30 2024-05-28 Bristol Myers Squibb Co Treatment of lag-3 positive tumors
KR20200010500A (en) 2017-05-30 2020-01-30 브리스톨-마이어스 스큅 컴퍼니 A composition comprising a combination of anti-LAG-3 antibodies, PD-1 pathway inhibitors, and immunotherapy agents
CN118356488A (en) 2017-05-30 2024-07-19 百时美施贵宝公司 Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
JOP20190279A1 (en) 2017-05-31 2019-11-28 Novartis Ag Crystalline forms of 5-bromo-2,6-di(1 h-pyrazol-1-yl)pyrimidin-4-amine and new salts
EP3630838A1 (en) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
US11566073B2 (en) 2017-06-01 2023-01-31 Bristol-Myers Squibb Company Methods of treating a tumor using an anti-PD-1 antibody
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
JP2020524694A (en) 2017-06-22 2020-08-20 ノバルティス アーゲー IL-1β binding antibodies for use in the treatment of cancer
MA49457A (en) 2017-06-22 2020-04-29 Novartis Ag CD73 BINDING ANTIBODY MOLECULES AND THEIR USES
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
TW201906866A (en) 2017-06-26 2019-02-16 英屬開曼群島商百濟神州有限公司 Treatment of abnormal bone condition in patients with acid sphingomyelinase deficiency
WO2019006007A1 (en) 2017-06-27 2019-01-03 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
CA3069524A1 (en) 2017-07-14 2019-01-17 Innate Tumor Immunity, Inc. Nlrp3 modulators
AU2018302283A1 (en) 2017-07-20 2020-02-06 Novartis Ag Dosage regimens of anti-LAG-3 antibodies and uses thereof
JP7186764B2 (en) 2017-07-28 2022-12-09 ブリストル－マイヤーズ スクイブ カンパニー Cyclic dinucleotides as anticancer agents
WO2019046498A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019046496A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
KR102674630B1 (en) 2017-08-31 2024-06-11 브리스톨-마이어스 스큅 컴퍼니 Cyclic dinucleotides as anticancer agents
AU2018326875A1 (en) 2017-09-04 2020-03-19 Agenus Inc. T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. Treatment regimen for cancers that are insensitive to bcl-2 inhibitors using the mcl-1 inhibitor alvocidib
US11660311B2 (en) 2017-10-10 2023-05-30 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
CN111247169A (en) 2017-10-15 2020-06-05 百时美施贵宝公司 Method for treating tumors
US11427610B2 (en) 2017-10-16 2022-08-30 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
KR20200084880A (en) 2017-11-06 2020-07-13 브리스톨-마이어스 스큅 컴퍼니 How to treat a tumor
MX2020004567A (en) 2017-11-06 2020-08-13 Genentech Inc Diagnostic and therapeutic methods for cancer.
CN109467603B (en) * 2017-11-14 2020-02-21 拜西欧斯（北京）生物技术有限公司 anti-PD-1 antibody and preparation method and application thereof
KR20200089286A (en) 2017-11-16 2020-07-24 노파르티스 아게 Combination therapy
CN111801334B (en) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 Treatment of indolent or invasive B-cell lymphomas using combinations comprising BTK inhibitors
RU2020121458A (en) 2017-11-30 2021-12-30 Новартис Аг CHIMERIC ANTIGEN RECEPTOR TARGETING BCMA AND ITS APPLICATIONS
US20210072244A1 (en) 2018-01-04 2021-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma resistant
CN112218651A (en) 2018-01-08 2021-01-12 诺华公司 Immunopotentiating RNA for combination with chimeric antigen receptor therapy
US20210363242A1 (en) 2018-01-16 2021-11-25 Bristol-Myers Squibb Company Methods of treating cancer with antibodies against tim3
CA3096287A1 (en) 2018-01-22 2019-07-25 Pascal Biosciences Inc. Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
BR112020014574A2 (en) 2018-01-22 2020-12-08 Bristol-Myers Squibb Company COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
WO2019152660A1 (en) 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
CN108314734B (en) * 2018-01-31 2021-11-05 中国药科大学 anti-PD-1 monoclonal antibody and application thereof
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
EP3756012A1 (en) 2018-02-21 2020-12-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
EP3762397B1 (en) 2018-03-08 2024-05-01 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
MX2020009550A (en) * 2018-03-22 2020-11-11 Keires Ag Antagonistic pd-1, pd-l1 and lag-3 binding proteins.
US11242393B2 (en) 2018-03-23 2022-02-08 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
EP3774911A1 (en) 2018-03-30 2021-02-17 Bristol-Myers Squibb Company Methods of treating tumor
US12110337B2 (en) 2018-04-04 2024-10-08 Bristol-Myers Squibb Company Anti-CD27 antibodies and uses thereof
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
KR102711180B1 (en) 2018-04-25 2024-09-26 인네이트 튜머 이뮤니티, 인코포레이티드 NLRP3 regulator
MA52363A (en) 2018-04-26 2021-03-03 Agenus Inc THERMAL SHOCK PROTEIN (HSP) PEPTIDIC COMPOSITIONS AND THEIR METHODS OF USE
AR126019A1 (en) 2018-05-30 2023-09-06 Novartis Ag ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
CN112384531B (en) 2018-06-01 2024-05-14 诺华股份有限公司 Binding molecules to BCMA and uses thereof
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
MA52968A (en) 2018-06-23 2021-04-28 Hoffmann La Roche METHODS OF TREATMENT OF LUNG CANCER USING A PD-1 AXIS ANTAGONIST, PLATINUM AGENT AND TOPOISOMERASE II INHIBITOR
JOP20210001A1 (en) 2018-07-10 2021-01-05 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
EP3823611A1 (en) 2018-07-18 2021-05-26 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
CN108948202A (en) * 2018-07-25 2018-12-07 博奥信生物技术（南京）有限公司 A kind of anti-human PD1 monoclonal antibody and application thereof
WO2020021061A1 (en) 2018-07-26 2020-01-30 Pieris Pharmaceuticals Gmbh Humanized anti-pd-1 antibodies and uses thereof
US20210238287A1 (en) 2018-07-26 2021-08-05 Bristol-Myers Squibb Company LAG-3 Combination Therapy for the Treatment of Cancer
JP2021534180A (en) 2018-08-16 2021-12-09 イネイト・テューマー・イミュニティ・インコーポレイテッドInnate Tumor Immunity, Inc. Substituted 4-amino-1H-imidazole [4,5-c] quinoline compound and improved method for its production
EP3837014B1 (en) 2018-08-16 2022-10-19 Innate Tumor Immunity, Inc. Imidazo[4,5-c]quinoline derived nlrp3-modulators
EP3837015B1 (en) 2018-08-16 2024-02-14 Innate Tumor Immunity, Inc. Imidazo[4,5-c]quinoline derived nlrp3-modulators
AU2019328632A1 (en) 2018-08-27 2021-03-25 Pieris Pharmaceuticals Gmbh Combination therapies comprising CD137/HER2 bispecific agents and PD-1 axis inhibitors and uses thereof
WO2020044252A1 (en) 2018-08-31 2020-03-05 Novartis Ag Dosage regimes for anti-m-csf antibodies and uses thereof
JP7535500B2 (en) 2018-09-03 2024-08-16 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Carboxamide and Sulfonamide Derivatives Useful as TEAD Modulators
WO2020049534A1 (en) 2018-09-07 2020-03-12 Novartis Ag Sting agonist and combination therapy thereof for the treatment of cancer
KR20210072059A (en) 2018-10-09 2021-06-16 브리스톨-마이어스 스큅 컴퍼니 Anti-MerTK Antibodies to Treat Cancer
US20210348238A1 (en) 2018-10-16 2021-11-11 Novartis Ag Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
WO2020081928A1 (en) 2018-10-19 2020-04-23 Bristol-Myers Squibb Company Combination therapy for melanoma
EP3870609A1 (en) 2018-10-23 2021-09-01 Bristol-Myers Squibb Company Methods of treating tumor
US20230053449A1 (en) 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
SG11202104969RA (en) 2018-11-16 2021-06-29 Bristol Myers Squibb Co Anti-nkg2a antibodies and uses thereof
EP3883964A1 (en) 2018-11-20 2021-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Bispecific antibody targeting transferrin receptor 1 and soluble antigen
WO2020104479A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
CN113167802A (en) 2018-12-04 2021-07-23 百时美施贵宝公司 Analytical method using in-sample calibration curves by multi-isotopologue reaction monitoring
EP3890749A4 (en) 2018-12-04 2022-08-03 Sumitomo Dainippon Pharma Oncology, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020115261A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2020120592A1 (en) 2018-12-12 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating melanoma
WO2020127411A1 (en) 2018-12-19 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
JP2022514315A (en) 2018-12-20 2022-02-10 ノバルティス アーゲー Dosage regimens and drug combinations containing 3- (1-oxoisoindoline-2-yl) piperidine-2,6-dione derivatives
WO2020128620A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
BR112021012037A2 (en) 2018-12-21 2021-11-03 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
MX2021007271A (en) 2018-12-21 2021-07-15 Onxeo New conjugated nucleic acid molecules and their uses.
CA3119584A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
EP3898676A1 (en) 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional anti-pd-1/sirpa molecule
EP3897613A1 (en) 2018-12-21 2021-10-27 Novartis AG Use of il-1beta binding antibodies
WO2020127885A1 (en) 2018-12-21 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for treating cancers and resistant cancers
AU2020208193A1 (en) 2019-01-14 2021-07-29 BioNTech SE Methods of treating cancer with a PD-1 axis binding antagonist and an RNA vaccine
JP7335341B2 (en) 2019-01-14 2023-08-29 イネイト・テューマー・イミュニティ・インコーポレイテッド NLRP3 modulator
EP3911417B1 (en) 2019-01-14 2022-10-26 Innate Tumor Immunity, Inc. Heterocyclic nlrp3 modulators , for use in the treatment of cancer
WO2020150116A1 (en) 2019-01-14 2020-07-23 Innate Tumor Immunity, Inc. Nlrp3 modulators
US20220089571A1 (en) 2019-01-14 2022-03-24 Innate Tumor Immunity, Inc. Nlrp3 modulators
CN113366316A (en) 2019-01-30 2021-09-07 国家医疗保健研究所 Methods and compositions for identifying whether a subject with cancer will acquire a response to an immune checkpoint inhibitor
US20220117911A1 (en) 2019-02-04 2022-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating blood-brain barrier
JP2022519385A (en) 2019-02-12 2022-03-23 ノバルティス アーゲー Pharmaceutical combination containing TNO155 and PD-1 inhibitor
WO2020167990A1 (en) 2019-02-12 2020-08-20 Tolero Pharmaceuticals, Inc. Formulations comprising heterocyclic protein kinase inhibitors
WO2020165370A1 (en) 2019-02-13 2020-08-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
JP7488826B2 (en) 2019-02-15 2024-05-22 ノバルティス アーゲー Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP7483732B2 (en) 2019-02-15 2024-05-15 ノバルティス アーゲー 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
CA3133460A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
WO2020198672A1 (en) 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Methods of treating tumor
WO2020198676A1 (en) 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Methods of treating tumor
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
CA3134522A1 (en) 2019-04-19 2020-10-22 Genentech, Inc. Anti-mertk antibodies and their methods of use
US20220220565A1 (en) 2019-04-30 2022-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
MA55805A (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc METHODS OF MODULATING IMMUNE ACTIVITY
WO2020231713A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2020231766A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
JP2022534981A (en) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー Cellular localization signatures and combination treatments
EP3976831A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
KR20220016155A (en) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 Methods of Identifying Suitable Subjects for Immuno-Oncology (I-O) Therapy
JP2022539208A (en) 2019-07-03 2022-09-07 スミトモ ファーマ オンコロジー， インコーポレイテッド Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
EP3998081A4 (en) 2019-07-05 2023-07-12 Ono Pharmaceutical Co., Ltd. Treatment of hematologic cancer with pd-1/cd3 dual specificity protein
WO2021026179A1 (en) 2019-08-06 2021-02-11 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021025140A1 (en) 2019-08-08 2021-02-11 小野薬品工業株式会社 Dual-specific protein
WO2021042019A1 (en) 2019-08-30 2021-03-04 Agenus Inc. Anti-cd96 antibodies and methods of use thereof
WO2021048292A1 (en) 2019-09-11 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
JP2022548881A (en) 2019-09-18 2022-11-22 ノバルティス アーゲー ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy
TW202124446A (en) 2019-09-18 2021-07-01 瑞士商諾華公司 Combination therapies with entpd2 antibodies
CA3153777A1 (en) 2019-09-22 2021-03-25 Bristol-Myers Squibb Company Quantitative spatial profiling for lag-3 antagonist therapy
AU2020353079A1 (en) 2019-09-25 2022-04-14 Bristol-Myers Squibb Company Composite biomarker for cancer therapy
MX2022003357A (en) 2019-09-25 2022-05-03 Seagen Inc Combination anti-cd30 adc, anti-pd-1 and chemotherapeutic for treatment of hematopoietic cancers.
EP4037714A1 (en) 2019-10-03 2022-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating macrophages polarization
WO2021074391A1 (en) 2019-10-17 2021-04-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing nasal intestinal type adenocarcinomas
IL292347A (en) 2019-10-21 2022-06-01 Novartis Ag Combination therapies with venetoclax and tim-3 inhibitors
AU2020370832A1 (en) 2019-10-21 2022-05-19 Novartis Ag TIM-3 inhibitors and uses thereof
EP4051286A1 (en) 2019-10-29 2022-09-07 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and compositions for treating uveal melanoma
JP2022553821A (en) 2019-11-05 2022-12-26 ブリストル－マイヤーズ スクイブ カンパニー M-protein assay and its use
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
CA3160479A1 (en) 2019-11-08 2021-05-14 Bristol-Myers Squibb Company Lag-3 antagonist therapy for melanoma
KR20220101138A (en) 2019-11-13 2022-07-19 제넨테크, 인크. Therapeutic compounds and methods of use
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides
US20230000864A1 (en) 2019-11-22 2023-01-05 Sumitomo Pharma Oncology, Inc. Solid dose pharmaceutical composition
WO2021119105A1 (en) 2019-12-09 2021-06-17 Seagen Inc. Combination therapy with liv1-adc and pd-1 antagonist
AU2020406083A1 (en) 2019-12-17 2022-06-16 Boehringer Ingelheim International Gmbh Bifunctional molecules comprising an IL-7 variant
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
KR20220118481A (en) 2019-12-19 2022-08-25 브리스톨-마이어스 스큅 컴퍼니 Combinations of DGK inhibitors and checkpoint antagonists
WO2021123243A1 (en) 2019-12-19 2021-06-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and vaccine compositions to treat cancers
CA3165399A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
US20230348458A1 (en) 2020-01-10 2023-11-02 Innate Tumor Immunity, Inc. Nlrp3 modulators
US20230076415A1 (en) 2020-01-17 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
US20230058489A1 (en) 2020-01-17 2023-02-23 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
WO2021152005A1 (en) 2020-01-28 2021-08-05 Universite De Strasbourg Antisense oligonucleotide targeting linc00518 for treating melanoma
WO2021152548A1 (en) 2020-01-30 2021-08-05 Benitah Salvador Aznar Combination therapy for treatment of cancer and cancer metastasis
JP2023512654A (en) 2020-01-31 2023-03-28 ジェネンテック， インコーポレイテッド Methods for Inducing Neoepitope-Specific T Cells Using PD-1 Axis Binding Antagonists and RNA Vaccines
US20230072528A1 (en) 2020-02-05 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
JP2023514152A (en) 2020-02-06 2023-04-05 ブリストル－マイヤーズ スクイブ カンパニー IL-10 and its uses
WO2021174091A1 (en) 2020-02-28 2021-09-02 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation
US20230113705A1 (en) 2020-02-28 2023-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, prognosing and managing treatment of breast cancer
JP2023516155A (en) 2020-02-28 2023-04-18 ノバルティス アーゲー Triple drug combinations containing dabrafenib, ERK inhibitors and RAF inhibitors or PD-1 inhibitors
CN115484958A (en) 2020-03-06 2022-12-16 赛尔基因昆蒂赛尔研究公司 Combination of LSD-1 inhibitor and nivolumab for the treatment of SCLC or SQNSCLC
KR20220151195A (en) 2020-03-06 2022-11-14 오엔에이 테라퓨틱스 에스.엘. Anti-CD36 antibodies and their use to treat cancer
US20230119066A1 (en) 2020-03-23 2023-04-20 Bristol-Myers Squibb Company Anti-ccr8 antibodies for treating cancer
EP4127139A1 (en) 2020-03-27 2023-02-08 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
IL296226A (en) 2020-04-21 2022-11-01 Novartis Ag Dosing regimen for treating a disease modulated by csf-1r
WO2021224438A1 (en) 2020-05-07 2021-11-11 Institut Curie Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
AR122644A1 (en) 2020-06-19 2022-09-28 Onxeo NEW CONJUGATED NUCLEIC ACID MOLECULES AND THEIR USES
US20230321067A1 (en) 2020-06-23 2023-10-12 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN116209677A (en) * 2020-06-26 2023-06-02 索伦托药业有限公司 anti-PD 1 antibodies and uses thereof
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
CN116133679A (en) 2020-06-30 2023-05-16 门德斯有限公司 Use of leukemia derived cells in ovarian cancer vaccines
WO2022008519A1 (en) 2020-07-07 2022-01-13 BioNTech SE Therapeutic rna for hpv-positive cancer
WO2022009157A1 (en) 2020-07-10 2022-01-13 Novartis Ag Lhc165 and spartalizumab combinations for treating solid tumors
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
JP2023535610A (en) 2020-07-28 2023-08-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Methods and compositions for preventing and treating cancer
JP2023536164A (en) 2020-08-03 2023-08-23 ノバルティス アーゲー Heteroaryl-substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2021331476A1 (en) 2020-08-28 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
US20230331848A1 (en) * 2020-08-31 2023-10-19 Biosion Inc. Pd-1 binding antibodies and uses thereof
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
IL300916A (en) 2020-08-31 2023-04-01 Bristol Myers Squibb Co Cell localization signature and immunotherapy
CA3189987A1 (en) 2020-09-02 2022-03-10 Pharmabcine Inc. Combination therapy of a pd-1 antagonist and an antagonist for vegfr-2 for treating patients with cancer
US20230365692A1 (en) 2020-09-24 2023-11-16 Merck Sharp & Dohme Llc Stable formulations of programmed death receptor 1 (pd-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof
US20230374064A1 (en) 2020-10-05 2023-11-23 Bristol-Myers Squibb Company Methods for concentrating proteins
US20230364127A1 (en) 2020-10-06 2023-11-16 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
EP4226377A1 (en) 2020-10-09 2023-08-16 Worldwide Innovative Network Novel prediction method and gene signatures for the treatment of cancer
WO2022086957A1 (en) 2020-10-20 2022-04-28 Genentech, Inc. Peg-conjugated anti-mertk antibodies and methods of use
US20240101666A1 (en) 2020-10-23 2024-03-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
WO2022084531A1 (en) 2020-10-23 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating glioma
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
WO2022094567A1 (en) 2020-10-28 2022-05-05 Ikena Oncology, Inc. Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
WO2022098628A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
JP7402381B2 (en) 2020-11-04 2023-12-20 ジェネンテック， インコーポレイテッド Administration for treatment with anti-CD20/anti-CD3 bispecific antibodies
AU2021374594A1 (en) 2020-11-04 2023-06-01 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag Cd19 binding molecules and uses thereof
WO2022101484A1 (en) 2020-11-16 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
WO2022101481A1 (en) 2020-11-16 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
CA3202523A1 (en) 2020-12-02 2022-06-09 Genentech, Inc. Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
TW202237119A (en) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Alk-5 inhibitors and uses thereof
IL303745A (en) 2020-12-17 2023-08-01 Ose Immunotherapeutics Bifunctional anti-pd1/il-7 molecules
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
IL303648A (en) 2020-12-28 2023-08-01 Bristol Myers Squibb Co Antibody compositions and methods of use thereof
CA3196999A1 (en) 2020-12-28 2022-07-07 Masano HUANG Methods of treating tumors
WO2022148781A1 (en) 2021-01-05 2022-07-14 Institut Curie Combination of mcoln activators and immune checkpoint inhibitors
WO2022157715A1 (en) 2021-01-22 2022-07-28 Dcprime B.V. Methods of tumor vaccination
EP4284510A1 (en) 2021-01-29 2023-12-06 Novartis AG Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
WO2022169921A1 (en) 2021-02-04 2022-08-11 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
JP2024510989A (en) 2021-03-12 2024-03-12 メンドゥス・ベスローテン・フェンノートシャップ Vaccination methods and use of CD47 blockers
EP4308118A1 (en) 2021-03-17 2024-01-24 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and compositions for treating melanoma
EP4308935A1 (en) 2021-03-18 2024-01-24 Novartis AG Biomarkers for cancer and methods of use thereof
TW202304506A (en) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
KR20240005700A (en) 2021-03-29 2024-01-12 주노 쎄러퓨티크스 인코퍼레이티드 Dosing and Treatment Methods Using Combination of Checkpoint Inhibitor Therapy and CAR T Cell Therapy
WO2022212784A1 (en) 2021-03-31 2022-10-06 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
TW202304979A (en) 2021-04-07 2023-02-01 瑞士商諾華公司 USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
US20240182571A1 (en) 2021-04-09 2024-06-06 Ose Immunotherapeutics New scaffold for bifunctional molecules with improved properties
PE20240327A1 (en) 2021-04-13 2024-02-22 Nuvalent Inc HETEROCYCLES WITH AMINO SUBSTITUTION TO TREAT CANCERS WITH EGFR MUTATIONS
EP4326903A1 (en) 2021-04-23 2024-02-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating cell senescence accumulation related disease
EP4330436A1 (en) 2021-04-30 2024-03-06 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
WO2022228705A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
AR125874A1 (en) 2021-05-18 2023-08-23 Novartis Ag COMBINATION THERAPIES
CN113030475B (en) * 2021-05-25 2021-08-10 泛肽生物科技(浙江)有限公司 T cell PD-1 detection method based on cell mitochondrial quality evaluation
WO2022256534A1 (en) 2021-06-03 2022-12-08 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
AU2022290563A1 (en) 2021-06-09 2024-01-25 Vivasor, Inc. Method of treating cancer by administration of an anti-pd-1 or anti-pd-l1 therapeutic agent via a lymphatic microneedle delivery device
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
TW202309078A (en) 2021-07-02 2023-03-01 美商建南德克公司 Methods and compositions for treating cancer
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
EP4377350A2 (en) 2021-07-28 2024-06-05 Genentech, Inc. Methods and compositions for treating cancer
MX2024001214A (en) 2021-07-28 2024-02-12 Hoffmann La Roche Methods and compositions for treating cancer.
IL309934A (en) 2021-07-30 2024-03-01 Ona Therapeutics S L Anti-cd36 antibodies and their use to treat cancer
TW202321308A (en) 2021-09-30 2023-06-01 美商建南德克公司 Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
IL311771A (en) 2021-10-06 2024-05-01 BioNTech SE Multispecific binding agents against pd-l1 and cd137 in combination
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
AU2022375806A1 (en) 2021-10-29 2023-12-14 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
WO2023078900A1 (en) 2021-11-03 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating triple negative breast cancer (tnbc)
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
CA3240096A1 (en) 2021-11-12 2023-05-19 Novartis Ag Combination therapy for treating lung cancer
WO2023097195A1 (en) 2021-11-24 2023-06-01 Genentech, Inc. Therapeutic indazole compounds and methods of use in the treatment of cancer
WO2023097194A2 (en) 2021-11-24 2023-06-01 Genentech, Inc. Therapeutic compounds and methods of use
CN118660964A (en) 2021-12-16 2024-09-17 瓦莱里奥治疗公司 Novel conjugated nucleic acid molecules and uses thereof
WO2023122573A1 (en) 2021-12-20 2023-06-29 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2023118165A1 (en) 2021-12-21 2023-06-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
IL314050A (en) 2022-01-26 2024-09-01 Bristol Myers Squibb Co Combination therapy for hepatocellular carcinoma
CN118765284A (en) 2022-02-25 2024-10-11 百时美施贵宝公司 Combination therapy for colorectal cancer
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
WO2023170606A1 (en) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023196987A1 (en) 2022-04-07 2023-10-12 Bristol-Myers Squibb Company Methods of treating tumor
WO2023196964A1 (en) 2022-04-08 2023-10-12 Bristol-Myers Squibb Company Machine learning identification, classification, and quantification of tertiary lymphoid structures
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023219613A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
TW202413412A (en) 2022-05-12 2024-04-01 丹麥商珍美寶股份有限公司 Binding agents capable of binding to cd27 in combination therapy
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
TW202417042A (en) 2022-07-13 2024-05-01 美商建南德克公司 Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020432A1 (en) 2022-07-19 2024-01-25 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4310197A1 (en) 2022-07-21 2024-01-24 Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy
WO2024023740A1 (en) 2022-07-27 2024-02-01 Astrazeneca Ab Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
WO2024033399A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sigmar1 ligand for the treatment of pancreatic cancer
WO2024033400A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sk2 inhibitor for the treatment of pancreatic cancer
WO2024049949A1 (en) 2022-09-01 2024-03-07 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
WO2024056716A1 (en) 2022-09-14 2024-03-21 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
WO2024069009A1 (en) 2022-09-30 2024-04-04 Alentis Therapeutics Ag Treatment of drug-resistant hepatocellular carcinoma
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
WO2024084034A1 (en) 2022-10-21 2024-04-25 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of osteoarthritis
TW202426505A (en) 2022-10-25 2024-07-01 美商建南德克公司 Therapeutic and diagnostic methods for cancer
WO2024105180A1 (en) 2022-11-16 2024-05-23 Boehringer Ingelheim International Gmbh Predictive efficacy biomarkers for anti-sirpa antibodies
WO2024116140A1 (en) 2022-12-01 2024-06-06 Medimmune Limited Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
WO2024115725A1 (en) 2022-12-01 2024-06-06 BioNTech SE Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
WO2024137589A2 (en) 2022-12-20 2024-06-27 Genentech, Inc. Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
WO2024137776A1 (en) 2022-12-21 2024-06-27 Bristol-Myers Squibb Company Combination therapy for lung cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024150177A1 (en) 2023-01-11 2024-07-18 Advesya Treatment methods for solid tumors
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies
WO2024175699A1 (en) 2023-02-23 2024-08-29 Imcheck Therapeutics Combination of btn3a activating antibody and immune checkpoint inhibitors
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2024200571A1 (en) 2023-03-28 2024-10-03 Institut National de la Santé et de la Recherche Médicale Method for discriminating mono-immunotherapy from combined immunotherapy in cancers
WO2024200826A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof
WO2024200823A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2024209072A1 (en) 2023-04-06 2024-10-10 Genmab A/S Multispecific binding agents against pd-l1 and cd137 for treating cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (en) 1991-06-03 1992-12-10 Behringwerke Ag TETRAVALENT BISPECIFIC RECEPTORS, THEIR PRODUCTION AND USE
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5750122A (en) * 1996-01-16 1998-05-12 The Procter & Gamble Company Compositions for treating hair or skin
EP2360254A1 (en) 1999-08-23 2011-08-24 Dana-Farber Cancer Institute, Inc. Assays for screening anti-pd-1 antibodies and uses thereof
AR036993A1 (en) 2001-04-02 2004-10-20 Wyeth Corp USE OF AGENTS THAT MODULATE THE INTERACTION BETWEEN PD-1 AND ITS LINKS IN THE SUBMODULATION OF IMMUNOLOGICAL ANSWERS
JP4409430B2 (en) * 2002-07-03 2010-02-03 小野薬品工業株式会社 Immunostimulatory composition
CN101899114A (en) * 2002-12-23 2010-12-01 惠氏公司 Anti-PD-1 antibody and uses thereof
US20050100965A1 (en) * 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
GB0400440D0 (en) 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
CN117534755A (en) * 2005-05-09 2024-02-09 小野药品工业株式会社 Human monoclonal antibodies to programmed death-1 (PD-1) and methods of treating cancer using anti-PD-1 antibodies
BRPI0611766A2 (en) 2005-06-08 2011-12-20 Dana Farber Cancer Inst Inc methods and compositions for the treatment of persistent infections and cancer by inhibition of the programmed cell death pathway
KR101888321B1 (en) * 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. Human monoclonal antibodies to programmed death ligand 1(pd-l1)
KR20090088891A (en) * 2006-11-15 2009-08-20 메다렉스, 인코포레이티드 Human monoclonal antibodies to btla and methods of use
NZ600758A (en) * 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
US8168757B2 (en) * 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer

Also Published As

Publication number Publication date
CN105683217B (en) 2019-12-10
US9676853B2 (en) 2017-06-13
CN111423511A (en) 2020-07-17
CA3175360C (en) 2024-05-28
JP2016521692A (en) 2016-07-25
WO2014194302A3 (en) 2015-02-26
US20170313776A1 (en) 2017-11-02
US20210130468A1 (en) 2021-05-06
US20220242954A1 (en) 2022-08-04
JP6997743B2 (en) 2022-02-04
CA2913977A1 (en) 2014-12-04
JP2023099773A (en) 2023-07-13
CA3175360A1 (en) 2014-12-04
US10584168B2 (en) 2020-03-10
WO2014194302A2 (en) 2014-12-04
CN111423511B (en) 2024-02-23
US11242391B2 (en) 2022-02-08
EP3004169A2 (en) 2016-04-13
EP3004169B1 (en) 2023-03-22
HK1238648A1 (en) 2018-05-04
EP3004169A4 (en) 2017-02-22
US20140356363A1 (en) 2014-12-04
JP2022027968A (en) 2022-02-14
JP2019214586A (en) 2019-12-19
CN105683217A (en) 2016-06-15
JP6563906B2 (en) 2019-08-21
CA2913977C (en) 2022-11-29

Similar Documents

Publication Publication Date Title
HK1238648A1 (en) Antigen binding proteins that bind pd-1
HUS2300036I1 (en) Antibodies that bind il-23
HK1204557A1 (en) Antigen binding proteins that bind pd-l1 pd-1
IL240838A0 (en) Anti-lag-3 binding proteins
HK1208236A1 (en) Antigen binding proteins that bind ccr2 ccr2
ZA201701912B (en) Antigen binding proteins that bind cxcr5
HK1208181A1 (en) Antigen binding proteins that bind c-met c-met
HK1217500A1 (en) Antibody specifically binding to her2 her2
HK1208474A1 (en) Antigen binding proteins that bind egfr egfr
HK1214283A1 (en) Antigen binding proteins that bind erbb3 erbb3
EP2855523A4 (en) Antigen binding proteins that bind dll-4
ZA201701941B (en) Antigen binding proteins that bind cxcr3
EP3131574A4 (en) Antigen binding proteins that bind wisp1
HK1208179A1 (en) Antigen binding proteins that bind igf1r igf1r
HK1218921A1 (en) Antibodies specifically binding to her3 her3